Late-Stage Biotech Relypsa, Inc. Seeks $138 Million in Upsized IPO
10/18/2013 8:24:12 AM
Relypsa, a late-stage biotech developing treatments for renal, cardiovascular and metabolic diseases, raised its deal size to $138 million and announced it will list under the ticker RLYP on Thursday. The Redwood City, CA-based company had previously filed to raise up to $127 million.elypsa was founded in 2007 and plans to list on the NASDAQ.
Help employers find you! Check out all the jobs and post your resume.
comments powered by